Omeq Medical

Omeq Medical

VP R&D Oded Tsamir (front) and CEO Lior Margalit (back) of Omeq Medical

The Need

Locating the epidural space that surrounds the spinal cord requires extensive physician training and relies heavily on feel. Drugs (“epidurals”) injected into this very narrow space (only 4 millimeters wide) are used for anesthesia and analgesic purposes both during and after surgery.

Many anesthesiologists use the Loss of Resistance (LoR) technique to confirm correct needle placement. Inaccurate needle placement occurs in up to 30% of cases, resulting in ineffective drug delivery, multiple insertions, and post-complications such as severe headaches or nerve damage.

To optimize epidural anesthesia and analgesia, the market seeks an objective method for detecting correct needle placement within the epidural space.

The Product

Omeq Medical is developing a single-use, smart epidural needle for safe, accurate epidural injections. Attached to a standard epidural needle, a special blunted probe repeatedly monitors the dynamic forces exerted by the surrounding tissues and accurately detects needle penetration into the epidural space. Once successful positioning is confirmed with a visual signal, the safety mechanism of the device protects the patient from inadvertent puncture of the spine.

The Advantages

  • Prevents multiple insertions, saves physician time
  • Improved analgesia/anesthesia success rate
  • Reduced needle placement complications
  • Used in conjunction with the LoR technique

 The Team

  • Lior Margalit, CEO: R&D and QA engineer, EndyMed, a medical device start-up; naval officer and captain, Israeli Navy; B.Sc., biomedical engineering, Ben-Gurion University of the Negev
  • Oded Tsamir, VP R&D: R&D engineer, Smart Medical System; IP manager, Solomon’s Seal; B.Sc., biomedical engineering, Ben-Gurion University of the Negev
  • Assaf Gur, CTO: Extensive experience in managing early-stage medical device companies; M.Sc., biomedical engineering, Tel Aviv University; B.Sc., software engineering and industrial management, Tel Aviv Engineering College
  • Daniel Levin, Ph.D., Business Advisor: Over 40 years’ experience in R&D and business management; CEO and founder, CoreFlow; Ph.D., aeronautical engineering, Technion-Israel Institute of Technology
  • Prof. Elon Eisenberg, Medical Advisor: Director of the Institute of Pain Medicine, Rambam Health Care Campus; Associate Professor of Neurology and Pain Medicine, Faculty of Medicine, Technion-Israel Institute of Technology; M.D., Sackler School of Medicine, Tel Aviv University; widely published
  • David Gichtin, M.D., Medical Advisor: Clinical Associate, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine Bayview Medical Center; anesthesiologist, Baltimore Pain Management Center; M.D., University of Kentucky College of Medicine; member of American Board of Anesthesiology and American Society of Pain Management

The Market

In the United States, over 20 million epidural injections are administered annually, with an additional 19 million injections in the rest of the world. Industry leaders B. Braun, Becton Dickinson, and Portex control this $1 billion global market with their standard epidural kits.

medical_omeq
Smart epidural needle

At a Glance

Stage: Technology development
Founded: April 2013
Investor: The Trendlines Group
IP: Patent in National phase, PCT, and provisional

In the Media

Named one of "6 captivating start-ups of 2013" (Globes)

Contact

Lior Margalit, CEO
Mobile: +972.54.431.5304
lior@omeqmedical.com
www.omeqmedical.com